ADIAL PHARMACEUTICALS, INC.
GLEN ALLEN, VA · Founded 2010 · CIK 0001513525 · Biotech · Public
Pharmaceutical therapeutics for alcohol use disorder treatment
adial.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $38M
- 19 Form D · Dec 2025
- 10 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $4,100,000 | |
| Private capital raised | Form D · SEC | $2,631,042 | |
| Private capital raised | Form D · SEC | $287,500 | |
| Private capital raised | Form D · SEC | $40,000 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $325,000 | |
| Private capital raised | Form D · SEC | $5,217,000 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $295,750 | |
| Private capital raised | Form D · SEC | $291,003 | |
| Private capital raised | Form D · SEC | $500,004 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $61,603 | |
| Private capital raised | Form D · SEC | $52,500 | |
| Private capital raised | Form D · SEC | $3,998,582 | |
| Private capital raised | Form D · SEC | $287,500 | |
| Private capital raised | Form D · SEC | $4,815,379 | |
| Private capital raised | Form D · SEC | $4,285,289 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1202 | Oncorus, Inc. | — | $47M |
| 1203 | Qlaris Bio, Inc. | — | $42M |
| 1204 | PLAKOUS THERAPEUTICS, INC. | — | $185K |
| 1205 | ADIAL PHARMACEUTICALS, INC. | — | $38M |
| 1206 | FORWARD DEFENSE, LLC | — | — |
| 1207 | Gigagen, Inc. | — | $36M |
| 1208 | Kodiak Sciences Inc. | — | $36M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- James AndersonDirector
- Robert CaponDirector
- Cary ClaiborneDirector · Executive Officer
- Robertson GillilandDirector
- Tony GoodmanDirector · Executive Officer
- Bankole JohnsonDirector · Executive Officer
- Mike KingDirector
- Ming LiDirector
- Leonard MeyerDirector
- James Newman, Jr.Director
- Jack ReichDirector
- John RiccardiDirector · Executive Officer
- Kevin SchuylerDirector
- Kevin Schuyler, CFADirector
- Vinay ShahExecutive Officer
- William StilleyDirector · Executive Officer
- William Stilley, IIIDirector · Executive Officer
- Joseph TruluckExecutive Officer
- Wendy YarnoDirector
Patents
- Ondansetron Treatment Of Alcohol Use Disorderapplication
- Ondansetron Treatment Of Alcohol Use Disorderapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.